Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 3, 2008, Pages 165-186

  Serock, Michelle R ^a   Wells, Amanda K ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Endothelium; Extracellular matrix; Hypertension; Sex hormones; Vascular smooth muscle

Indexed keywords

2,3 BIS(4 HYDROXYPHENYL)PROPIONITRILE; 4,4',4'' [4 PROPYL [(1)H]PYRAZOLE 1,3,5 TRIYL]TRIS PHENOL; BIOCHANIN A; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIETHYLSTILBESTROL; DROSPIRENONE; EQUOL; ESCLIM; ESTRADIOL; ESTRADIOL BENZOATE; ESTRADIOL CIPIONATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; FEMRING; FULVESTRANT; GINSENOSIDE; GYNODIOL; HORMONE RECEPTOR STIMULATING AGENT; ISOFLAVONE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; PHYTOESTROGEN; PLACEBO; PREMPAC; PROGESTERONE; RALOXIFENE; SECOISOLARICIRESINOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STILBENE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD VESSEL INJURY; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ESTROGEN DEFICIENCY; EXTRACELLULAR MATRIX; GENETIC POLYMORPHISM; HEART PROTECTION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VENOUS THROMBOEMBOLISM;

EID: 85042587042     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008786263970     Document Type: Review

References (239)

1. Jayachandran M, Miller MM. Mechanisms of estrogenic vascular protection. Am J Physiol Heart Circ Physiol 2006; 290: H507-H508.
2. Koledova VV, Khalil RA. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther 2007; 5(4): 777-789.
3. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004; 286(2): R233-R249.
4. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002; 90(1A): 3F-6F.
5. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308(5728): 1583-1587.
6. Kim JK, Levin ER. Estrogen signaling in the cardiovascular system. Nucl Recept Signal 2006; 4: e013.
7. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. J Biol Chem 2005; 280(20): 19704-19710.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
10. Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 2004; 44(6): 789-795.
11. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002; 16(5): 938-946.
12. Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. J Cell Physiol 2007; 213(3): 610-617.
13. Matthews J, Gustafsson JA. Estrogen signaling: A subtle balance between ER alpha and ER beta. Mol Interv 2003; 3(5): 281-92.
14. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen 2receptor beta: An overview and update. Nucl Recept Signal 2008; 6: e003.
15. Pettersson K, Gustafsson J. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001; 63: 165-192.
16. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: From concept to therapeutic targeting. Mol Interv 2005; 5(6): 343-357.
17. Pike ACW, Brzozowski AM, Hubbard RE, et al. Structure of the lingand-binding domain of oestrogen receptor beta in the presence of a patrial agonist and a full agonist. EMBO 1999; 18(17): 4608-4618.
18. Miller VM, Mulvagh SL. Sex steroids and endothelial function: Translating basic science to clinical practice. Trends Pharmacol Sci 2007; 28(6): 263-270.
19. Alevizaki M, Saltiki K, Cimponeriu A, et al. Severity of cardiovascular disease in postmenopausal women: Associations with common estrogen receptor alpha polymorphic variants. Eur J Endocrinol 2007; 156(4): 489-496.
20. Jakimiuk AJ, Bogusiewicz M, Skorupski P, et al. Relationship between estrogen receptor-alpha polymorphism and serum levels of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, C-reactive protein and homocysteine in postmenopausal women. Gynecol Endocrinol 2007; 23(10): 584-589.
21. Emre A, Sahin S, Erzik C, et al. Effect of hormone replacement therapy on plasma lipoproteins and apolipoproteins, endothelial function and myocardial perfusion in postmenopausal women with estrogen receptor-alpha IVS1-397 C/C genotype and established coronary artery disease. Cardiology 2006; 106(1): 44-50.
22. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346(13): 967-974.
23. Peter I, Kelley-Hedgepeth A, Fox CS, et al. Variation in estrogen-related genes associated with cardiovascular phenotypes and circulating estradiol, testosterone, and dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 2008; 93(7): 2779-2785.
24. Han G, Yu X, Lu L, et al. Estrogen receptor alpha mediates acute potassium channel stimulation in human coronary artery smooth muscle cells. J Pharmacol Exp Ther 2006; 316(3): 1025-1030.
25. Chen DB, Bird IM, Zheng J, Magness RR. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 2004; 145(1): 113-125.
26. Mompéo B, Tscheuschilsuren G, Ausst G, Metz S, Spanel-Borowski K. Estrogen receptor expression and synthesis in the human internal thoracic artery. Ann Anat 2003; 185(1): 57-65.
27. Stamatelopoulos KS, Lekakis JP, Poulakaki NA, et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 2004; 147(6): 1093-1099.
28. Nakamura Y, Suzuki T, Miki Y, et al. Estrogen receptors in atherosclerotic human aorta: Inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol Cell Endocrinol 2004; 219(1-2): 17-26.
29. Darblade B, Pendaries C, Krust A, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-,estrogen receptor. Circ Res 2002; 90(4): 413-419.
30. Eyster KM, Mark CJ, Gayle R, Martin DS. The effects of estrogen and testosterone on gene expression in the rat mesenteric arteries. Vascul Pharmacol 2007; 47(4): 238-247.
31. Tsang SY, Yao X, Chan HY, et al. Tamoxifen and estrogen attenuate enhanced vascular reactivity induced by estrogen deficiency in rat carotid arteries. Biochem Pharmacol 2007; 73(9): 1330-1339.
32. Liao WX, Magness RR, Chen DB. Expression of estrogen receptors-alpha and -beta in the pregnant ovine uterine artery endothelial cells in vivo and in vitro. Biol Reprod 2005; 72: 530-537.
33. Rayner K, Chen YX, Hibbert B, et al. Discovery of NM23-H2 as an estrogen receptor beta-associated protein: Role in estrogen-induced gene transcription and cell migration. J Steroid Biochem Mol Biol 2008; 108(1-2): 72-81.
34. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids 2002; 67: 471-475.
35. Evinger AJ, Levin ER. Requirements for estrogen receptor alpha membrane localization and function. Steroids 2005; 70(5-7): 361-363.
36. Moriarty K, Kim KH, Bender JR. Minireview: Estrogen receptor-mediated rapid signaling. Endocrinology 2006; 147(12): 5557-5563.
37. Muller-Delp JM, Lubahn DB, Nichol KE, et al. Regulation of nitric oxide-dependent vasodilation in coronary arteries of estrogen receptor-alpha-deficient mice. Am J Physiol Heart Circ Physiol 2003; 285(5): H2150-H2157.
38. Douglas G, Cruz MN, Poston L, Gustafsson JA, Kublickiene K. Functional characterization and sex differences in small mesenteric arteries of the estrogen receptor-beta knockout mouse. Am J Physiol Regul Integr Comp Physiol 2008; 294(1): R112-R120.
39. Cruz MN, Douglas G, Gustafsson JA, Poston L, Kublickiene K. Dilatory responses to estrogenic compounds in small femoral arteries of male and female estrogen receptor-beta knockout mice. Am J Physiol Heart Circ Physiol 2006; 290(2): H823-H829.
40. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: Unanswered questions and some speculations. Hypertension 2005; 45(2): 170-174.
41. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res 2003; 93(5): 399-405.
42. O'Dowd BF, Nguyen T, Marchese A, et al. Discovery of three novel G-protein coupled receptor genes. Genomics 1998; 47(2): 310-313.
43. Haas E, Meyer MR, Schurr U, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007; 49(6): 1358-1363.
44. Revenkar CM, Cimino DF, Skylar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.
45. Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Comm 2006; 346: 904-910.
46. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: A potential novel mechnism of endocrine disruption. J Steroid Biochem Mol Biol 2006; 102(1-5): 175-179.
47. Filardo E, Quinn J, Pang Y, et al. Activation of the novel estrogen receptor G protein coupled receptor 3- (GPR30) at the plasma membrane. Endocrinology 2007; 148(7): 3236-3245.
48. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol 2007; 265-266: 138-142.
49. Revenkar CM, Mitchell HD, Field AS, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol 2007; 2(8): 536-544.
50. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: A transmembrane estrogen receptor. J Steroid Biochem Mol Biol 2008; 109(3-5): 350-353.
51. Otto C, Rohde-Schulz B, Schwarz G, et al. GPR30 localizes to the endoplasmic recticulum and is not activated by estradiol. Endocrinology 2008.
52. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006; 20(9): 1996-2000.
53. Klinge CM, Jernigan SC, Mattingly KA, Risinger KE, Zhang J. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J Mol Endocrinol 2004; 33(2): 387-410.
54. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006; 7(8): 497-508.
55. Ramsey TL, Risinger KE, Jernigan SC, Mattingly KA, Klinge CM. Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner. Endocrinology 2004; 145(1): 149-160.
56. Bolego C, Vegeto E, Pinna C, Maggi A, Cignarella A. Selective agonists of estrogen receptor isoforms: New perspectives for cardiovascular disease. Arterioscler Thromb Vasc Biol 2006; 26(10): 2192-2199.
57. Siow RC, Li FY, Rowlands DJ, de Winter P, Mann GE. Cardiovascular targets for estrogens and phytoestrogens: Transcriptional regulation of nitric oxide synthase and antioxidant defense genes. Free Radic Biol Med 2007; 42(7): 909-925.
58. Mann GE, Rowlands DJ, Li FY, de Winter P, Siow RC. Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res 2007; 75(2): 261-274.
59. Cheskis BJ, Greger J, Cooch N, et al. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 2008; 73(9-10): 901-905.
60. Kim KH, Moriarty K, Bender JR.Vascular cell signaling by membrane estrogen receptors. Steroids. 2008; 73(9-10): 864-869.
61. Barbacanne MA, Rami J, Michel JB, et al. Estradiol increases rat aorta endothelium-derived relaxing factor (EDRF) activity without changes in endothelial NO synthase gene expression: Possible role of decreased endothelium-derived superoxide anion production. Cardiovasc Res 1999; 41(3): 672-681.
62. Luksha L, Poston L, Gustafsson JA, Hultenby K, Kublickiene K. The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J Physiol 2006; 577(3): 945-955.
63. Liu HM, Zhao XF, Guo LN, Tan Z, Wang TH. Effects of caveolin-1 on the 17beta-estradiol-mediated inhibition of VSMC proliferation induced by vascular injury. Life Sci 2007; 80: 800-812.
64. Leung FP, Tsang SY, Wong CM, et al. Raloxifene, tamoxifen and vascular tone. Clin Exp Pharmacol Physiol 2007; 34(8): 809-813.
65. Han G, Ma H, Chintala R, et al. Nongenomic, endothelium-independent effects of estrogen on human coronary smooth muscles are mediated by type I (neuronal) NOS and PI3-kinase-Akt signaling. Am J Physiol Heart Circ Physiol 2007; 293(1): H314-H321.
66. Nakaya Y, Mawatari K, Takahashi A, Harada N, Hata A, Yasui S. The phytoestrogen Ginsenoside Re activates potassium channels of vascular smooth muscle cells through PI3K/Akt and nitric oxide pathways. J Med Invest 2007; 54(3-4): 381-384.
67. White RE, Darkow DJ, Lang JL. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995; 77(5): 936-942.
68. Traupe T, Stettler CD, Li H, et al. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 2007; 49(6): 1364-1370.
69. Ho KJ, Liao JK. Non-nuclear actions of estrogen: New targets for prevention and treatment of cardiovascular disease. Mol Interv 2002; 2(4): 219-228.
70. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75(2): 346-359.
71. Chancey AL, Gardner JD, Murray DB, Brower GL, Janicki JS. Modulation of cardiac mast cell-mediated extracellular matrix degradation by estrogen. Am J Physiol Heart Circ Physiol 2005; 289(1): H316-H321.
72. Simoncini T, Scorticati C, Mannella P, et al. Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 2006; 20(8): 1756-1771.
73. Zhou L, Shao Y, Huang Y, Yao T, Lu LM. 17beta-estradiol inhibits angiotensin II-induced collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors. Eur J Pharmacol 2007; 567(3): 186-192.
74. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr Rev 2006; 27(6): 575-605.
75. Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005; 28(7): 579-584.
76. Gao H, Liang M, Bergdahl A, et al. Estrogen attenuates vascular expression of inflammation associated genes and adhesion of monocytes to endothelial cells. Inflamm Res 2006; 55(8): 349-353.
77. Geraldes P, Gagnon S, Hadjadj S, et al. Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: An ERalpha-mediated pathway. Cardiovasc Res 2006; 71(3): 566-573.
78. Xing D, Feng W, Miller AP, et al. Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol 2007; 292(6): H2607-H2612.
79. Pfeilschifter J, Köditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23(1): 90-119.
80. Corrado E, Rizzo M, Muratori I, Coppola G, Novo S. Older age and markers of inflammation are strong predictors of clinical events in women with asymptomatic carotid lesions. Menopause 2008; 15(2): 240-247.
81. Christian RC, Liu PY, Harrington S, Ruan M, Miller VM, Fitzpatrick LA. Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J Clin Endocrinol Metab 2006; 91: 2713-2720.
82. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: New perspectives for estrogen receptor signaling. Hypertension 2006; 47(6): 1019-1026.
83. Kim J, Kim JY, Song KS, et al. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta 2007; 1772(1): 72-80.
84. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005; 66(2): 295-306.
85. Kublickiene K, Svedas E, Landgren BM, et al. Small artery endothelial dysfunction in postmenopausal women: in vitro Function, morphology, and modification by estrogen and selective estrogen receptor modulators. J Clin Endocrinol Metab 2005; 90(11): 6113-6122.
86. Kublickiene K, Fu XD, Svedas E, Landgren BM, Genazzani AR, Simoncini T. Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab 2008; 93(5): 1874-1883.
87. Wynne FL, Payne JA, Cain AE, Reckelhoff JF, Khalil RA. Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension 2004; 43(2): 405-412.
88. Sherwood A, Bower JK, McFetridge-Durdle J, Blumenthal JA, Newby LK, Hinderliter AL. Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol 2007; 27(8): 1782-1787.
89. Egami R, Tanaka Y, Nozaki M, Koera K, Okuma A, Nakano H. Chronic treatment with 17beta-estradiol increases susceptibility of smooth muscle cells to nitric oxide. Eur J Pharmacol 2005; 520(1-3): 142-149.
90. Arruda CG, Aldrighi JM, Bortolotto LA, Alecrin IN, Ramires JA. Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women. Gynecol Endocrinol 2006; 22(10): 557-563.
91. Ho JY, Chen MJ, Sheu WH, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod 2006; 21(10): 2715-2720.
92. Hu P, Greendale GA, Palla SL, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: The postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 2006; 185(2): 347-352.
93. Hsia J, Criqui MH, Herrington DM, et al. Conjugated equine estrogens and peripheral arterial disease risk: The Women's Health Initiative. Am Heart J 2006; 152(1): 170-176.
94. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006; 113(20): 2425-2434.
95. Lemaitre RN, Weiss NS, Smith NL, et al. Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med 2006; 166(4): 399-404.
96. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292(13): 1581-1587.
97. Khazaei M, Nematbakhsh M. Serum level of vascular endothelial growth factor is increased by estrogen replacement therapy in normotensive and DOCA-Salt hypertensive ovariectomized rats. Clin Chim Acta 2006; 365(1-2): 206-210.
98. Gargett CE, Zaitseva M, Bucak K, Chu S, Fuller PJ, Rogers PA. 17Beta-estradiol up-regulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: role of estrogen receptor-alpha and -beta. J Clin Endocrinol Metab 2002; 87(9): 4341-4349.
99. Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, et al. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. Climacteric 2007; 10(5): 400-407.
100. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21(9): 1512-1519.
101. Cerquetani E, Vitale C, Mercuro G, Fini M, Zoncu S, Rosano GM. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk. Gynecol Endocrinol 2004; 18(6): 291-298.
102. Rosano GM, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: The evidence. Climacteric 2007; 10(1): 19-24.
103. Mallareddy M, Hanes V, White WB. Drospirenone, a new progestogen, for postmenopausal women with hypertension. Drugs Aging 2007; 24(6): 453-466.
104. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: A randomized, double-blind, multicenter trial. Menopause 2005; 12(6): 716-727.
105. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48(2): 246-253.
106. Duvernoy CS, Rose PA, Kim HM, Kehrer C, Brook RD. Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: A pilot study. J Womens Health (Larchmt) 2007; 16(7): 963-970.
107. Dubey RK, Jackson EK, Gillespie DG, et al. Medroxyprogesterone abrogates the inhibitory effects of estradiol on vascular smooth muscle cells by preventing estradiol metabolism. Hypertension 2008; 51(4): 1197-1202.
108. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstetrics & Gynecology 1996; 87(5): 897-904.
109. Duffy C, Perez K, Partridge A. Implications of phytoiestrogen intake for breast cancer. Cancer J Clin 2007; 57: 260-277.
110. Hallund J, Tetens I, Bugel S, Tholstrup T, Bruun JM. The effect of a lgnan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women. Nutr Metab Cardiovasc Dis 2008; 18(7): 497-502.
111. Oh KS, Choi YH, Ryu SY, et al. Cardiovascular effects of lignans isolated from Saururus chinensis. Planta Med 2008: 74(3): 233-8.
112. Hallund J, Bügel S, Tholstrup T, et al. Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Br J Nutr 2006; 95(6): 1120-1126.
113. West SG, Hilpert KF, Juturu V, et al. Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement therapy. J Womens Health (Larchmt) 2005; 14(3): 253-262.
114. Usui T. Pharmaceutical prospects of phytoestrogens. Endocr J 2006; 53(1): 7-20.
115. Squadrito F, Altavilla D, Morabito N, et al. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 2002; 163(2): 339-347.
116. Cruz MN, Luksha L, Logman H, Poston L, Agewall S, Kublickiene K. Acute responses to phytoestrogens in small arteries from men with coronary heart disease. Am J Physiol Heart Circ Physiol 2006; 290(5): H1969-H1975.
117. Homma N, Morio Y, Takahashi H, et al. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension. Respiration 2006; 73(1): 105-112.
118. Vera R, Jiménez R, Lodi F, et al. Genistein restores caveolin-1 and AT-1 receptor expression and vascular function in large vessels of ovariectomized hypertensive rats. Menopause 2007; 14(5): 933-940.
119. Li HF, Wang LD, Qu SY. Phytoestrogen genistein decreases contractile response of aortic artery in vitro and arterial blood pressure in vivo. Acta Pharmacol Sin 2004; 25(3): 313-318.
120. Woodman OL, Missen MA, Boujaoude M. Daidzein and 17 beta-estradiol enhance nitric oxide synthase activity associated with an increase in calmodulin and a decrease in caveolin-1. J Cardiovasc Pharmacol 2004; 44(2): 155-163.
121. Si H, Liu D. Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. J Nutr 2008; 138(2): 297-304.
122. Simoncini T, Garibaldi S, Fu XD, et al. Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. Menopause 2008; 15(3): 542-550.
123. Jackman KA, Woodman OL, Chrissobolis S, Sobey CG. Vasorelaxant and antioxidant activity of the isoflavone metabolite equol in carotid and cerebral arteries. Brain Res 2007; 1141: 99-107.
124. 2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem 2006; 281(37): 27335-27345.
125. Chin-Dusting JPF, Fisher LJ, Lewis TV, Piekarska A, Nestel P, Husband A. The vascular activity of some isoflacone metabolites:implications for a cardioprotective role. Br J Pharmacol 2001; 133: 595-605.
126. Shen J, White M, Husband AJ, Hambly BD, Bao S. Phytoestrogen derivatives differentially inhibit arterial neointimal proliferation in a mouse model. Eur J Pharmacol 2006; 548(1-3): 123-128.
127. Dai S, Duan J, Lu Y, et al. Phytoestrogen alpha-zearalanol inhibits atherogenesis and improves lipid profile in ovariectomized cholesterol-fed rabbits. Endocrine 2004; 25(2): 121-129.
128. Altavilla D, Saitta A, Galeano M, et al. The phytoestrogen alpha-zearalenol reverses endothelial dysfunction induced by oophorectomy in rats. Lab Invest 2001; 81(2): 125-132.
129. Cornwell T, Cohick W, Raskin I. Dietary Phytoestrogens and Health. Phytochemistry 2004; 65(8): 995-1016.
130. Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008; 300(11): 1303-1310.
131. Hall WL, Vafeiadou K, Hallund J, et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: Interactions with genotype and equol production. Am J Clin Nutr 2005; 82(6): 1260-1268.
132. Liu C, Tazzeo T, Lippton H, Janssen LJ. Role of tyrosine phosphorylation in U46619-induced vasoconstriction of pulmonary vasculature and its modulation by genistein, daidzein, and equol. J Cardiovasc Pharmacol 2007; 50(4): 441-448.
133. Rowland I, Faughnan M, Hoey L, Wähälä K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. Br J Nutr 2003; 89 Suppl 1: S45-S58.
134. Vogelvang TE, van der Mooren MJ, Mijatovic V, Kenemans P. Emerging selective estrogen receptor modulators: Special focus on effects on coronary heart disease in postmenopausal women. Drugs 2006; 66(2): 191-221.
135. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002; 105(11): 1368-1373.
136. Choi BG, Vilahur G, Zafar MU, et al. Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis 2008.
137. Abu-Fanne R, Brzezinski A, Golomb M, et al. Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice. Menopause 2008; 15(1): 98-104.
138. Leung HS, Seto SW, Kwan YW, et al. Endothelium-independent relaxation to raloxifene in porcine coronary artery. Eur J Pharmacol 2007; 555(2-3): 178-184.
139. Wang TH, Xiang QL, Chen JW, Pan H, Cui YH. Raloxifene plus 17beta-estradiol inhibits proliferation of primary cultured vascular smooth muscle cells and human mammary endothelial cells via the janus kinase/signal transducer and activator of transcription3 cascade. Eur J Pharmacol 2007; 561(1-3): 7-13.
140. Katz DL, Evans MA, Njike VY, et al. Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. Climacteric 2007; 10(6): 500-507.
141. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003; 42(4): 698-704.
142. Pines A. Lessons from RUTH. Climacteric 2006; 9(5): 323-324.
143. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008; 99(2): 338-342.
144. Tsuda K, Nishio I. A selective estrogen receptor modulator, tamoxifen, and membrane fluidity of erythrocytes in normotensive and hypertensive postmenopausal women: an electron paramagnetic resonance investigation. Am J Hypertens 2005; 18(8): 1067-1076.
145. Park S, Kim B, Kim J, et al. Tamoxifen induces vasorelaxation via inhibition of mitogen-activated protein kinase in rat aortic smooth muscle. J Vet Med Sci 2003; 65(11): 1155-1160.
146. Leung SW, Teoh H, Keung W, Man RY. Non-genomic vascular actions of female sex hormones: Physiological implications and signalling pathways. Clin Exp Pharmacol Physiol 2007; 34(8): 822-826.
147. Kallás HC, Aldrighi JM, Kallás E, Franchini Ramires JA. Repercussions of raloxifen, tamoxifen and estrogen on aortic atherosclerotic lesions of female rabbits submitted to ovariectomy and hypercholesterol diet. Maturitas 2005; 50(1): 30-38.
148. Filardo EJ, Thomas P. GRP30: A 7 transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005; 16(8): 363-367.
149. Stauffer SR, Coletta CJ, Tedesco R, et al. Pyrazole ligands: Structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 2000; 43(26): 4934-4947.
150. Traupe T, Stettler CD, Li H, et al. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 2007; 49(6): 1364-1370.
151. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001; 44(24): 4230-4251.
152. Nikolic I, Liu D, Bell JA, Collins J, Steenbergen C, Murphy E. Treatment with an estrogen receptor-beta-selective agonist is cardioprotective. J Mol Cell Cardiol 2007; 42(4): 769-780.
153. Schrepfer S, Deuse T, Münzel T, Schäfer H, Braendle W, Reichenspurner H. The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity. Menopause 2006; 13(3): 489-499.
154. Montgomery S, Shaw L, Pantelides N, Taggart M, Austin C. Acute effects of oestrogen receptor subtype-specific agonists on vascular contractility. Br J Pharmacol 2003; 139: 1249-1253.
155. Bolego C, Cignarella A, Sanvito P, et al. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. J Pharmacol Exp Ther 2005; 313(3): 1203-1208.
156. Ba ZF, Lu A, Shimizu T, et al. 17beta-Estradiol modulates vasoconstriction induced by endothelin-1 following trauma-hemorrhage. Am J Physiol Heart Circ Physiol 2007; 292(1): H245-H250.
157. Jazbutyte V, Arias-Loza PA, Hu K, et al. Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res 2008; 77(4): 774-781.
158. Al Zubair K, Razak A, Bexis S, Docherty JR. Relaxations to oestrogen receptor subtype selective agonists in rat and mouse arteries. Eur J Pharmacol 2005; 513(1-2): 101-108.
159. Pinna C, Bolego C, Sanvito P, et al. Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta. J Pharmacol Exp Ther 2006; 319(3): 1444-1451.
160. Bakir S, Mori T, Durand J, Chen YF, Thompson JA, Oparil S. Estrogen-induced vasoprotection is estrogen receptor dependent: Evidence from the balloon-injured rat carotid artery model. Circulation 2000; 101(20): 2342-2344.
161. Leung HS, Yung LM, Leung FP, et al. Tamoxifen dilates porcine coronary arteries: Roles for nitric oxide and ouabain-sensitive mechanisms. Br J Pharmacol 2006; 149(6): 703-711.
162. Scott PA, Tremblay A, Brochu M, St-Louis J. Vasorelaxant action of 17 -estradiol in rat uterine arteries: Role of nitric oxide synthases and estrogen receptors. Am J Physiol Heart Circ Physiol 2007; 293(6):
163. Moritz A, Radtke OA, Gust R, Glusa E, Pertz HH. Characterisation of the relaxant response to raloxifene in porcine coronary arteries. Eur J Pharmacol 2006; 545(2-3): 153-160.
164. Gouva L, Tsatsoulis A. The role of estrogens in cardiovascular disease in the aftermath of clinical trials. Hormones (Athens) 2004; 3(3): 171-183.
165. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 2007; 14(6): 978-984.
166. Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008; 115(2): 169-175.
167. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8(1): 3-12.
168. Mercuro G, Vitale C, Fini M, Zoncu S, Leonardo F, Rosano GM. Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: A randomized trial. Int J Cardiol 2003; 89(2-3): 257-265.
169. Koh KK, Shin MS, Sakuma I, et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24(8): 1516-1521.
170. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24(3): 571-576.
171. Appt SE, Clarkson TB, Lees CJ, Anthony MS. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas 2006; 55(2): 187-194.
172. Vitale C, Mercuro G, Cerquetani E, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol 2008; 28(2): 348-352.
173. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477.
174. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006; 15(1): 35-44.
175. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): A randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335(7613): 239.
176. Sanz-González SM, Cano A, Valverde MA, Hermenegildo C, Andrés V. Drug targeting of estrogen receptor signaling in the cardiovascular system: preclinical and clinical studies. Curr Med Chem Cardiovasc Hematol Agents 2004; 2(2): 107-122.
177. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53(3): 605-619.
178. Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007; 14(2): 251-260.
179. Szmuilowicz ED, Adler GK, Ricchiuti V, Hopkins PN, Seely EW. Relationships between endogenous sex hormone concentrations and vascular function in postmenopausal women. J Clin Endocrinol Metab 2007; 92(12): 4738-4741.
180. Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells.Endocrinology. 2004; 145(12): 5745-5756.
181. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR. in vitro Effects of progesterone and progestins on vascular cells. Steroids 2003; 68(10-13): 831-836.
182. Simoncini T, Fu XD, Caruso A, et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007; 22(8): 2325-2334.
183. Sitruk-Ware R. New progestogens: A review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004; 21(13): 865-883.
184. Thomas T, Rhodin J, Clark L, Garces A. Progestins initiate adverse events of menopausal estrogen therapy. Climacteric 2003; 6(4): 293-301.
185. Pedersen NG, Pedersen SH, Dalsgaard T, Lund CO, Nilas L, Ottesen B. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits. Maturitas 2004; 49(4): 304-314.
186. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 2007; 21(1): 265-273.
187. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur J Endocrinol 2007; 156(6): 687-693.
188. Khatibi A, Agardh CD, Shakir YA, et al. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study. Climacteric 2007; 10(5): 386-92.
189. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis 2007; 18(1): 9-13.
190. Akishita M, Hashimoto M, Ohike Y, et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res 2008; 31(1): 69-74.
191. Simon JA. Safety of estrogen/androgen regimens. J Reprod Med 2001; 46(3): 281-290.
192. Chiuve SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. J Clin Endocrinol Metab 2004; 89(5): 2207-2213.
193. Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res 2008; 31(2): 71-79.
194. Störk S, Bots ML, Grobbee DE, van der Schouw YT. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med 2008; 264(3): 245-253.
195. Hak AE, Westendorp IC, Pols HA, Hofman A, Witteman JC.High-dose testosterone is associated with atherosclerosis in postmenopausal women. Maturitas 2007; 56(2): 153-160.
196. U.S. Food and Drug Administration. FDA Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. May 6, 2008.
197. Miller, C.P., Collini, M.D., Tran, B.D.: US5880137 (1999).
198. Miller, C.P., Collini, M.D., Harris, H.A., Keith, J.C.: US20036559177 (2003).
199. Raveendranath, P.C, Wichtowski, J.A.: US5210081 (1993).
200. Dodge, J.A., Stocksdale, M.G.: US20006060488 (2000).
201. Jacobsen, P., Treppendahl, S., Bury, P.S., Kanstrup, A., Christiansen, L.B.: US20016316494 (2001).
202. Potter, S.M., Henley, E.C., Waggle, D.H.: US5855892 (1999).
203. Loser, R., Schliak, M., Thompson, D.D.: US5827892 (1998).
204. Thompson, D.D.: US5441986 (1995).
205. Hughes, C.L., Henley, E.C., Larkson, T.B.: US5516528 (1996).
206. Gainger, D.J., Metcalfe, J.C., Kunz, L.L., Schroff, R.W., Weissberg, P.L.: US5770609 (1998).
207. Grainger, D.J., Metcalfe, Weissberg, P.L.: US20016251920 (2001).
208. Huebner, V.D., Lin, X., James, I., Chen, L., Desai, M., Moore, J.C., Krywult, B., Navaratnam, T., Singh, R., Trainor, R., Wang, L.: US20016262098 (2001).
209. Bhagwat, S.S., McKie, J.A., Khammungkhune, S.: US20016331562 (2001).
210. Huebner, V.D., Lin, X., James, I., Chen, L., Desai, N., Krywult, B., Singh, R., Wang, L.: US20016291505 (2001).
211. Cameron, K.O., Dasilva-Jardine, P.A., Ke, H.Z., Rosati, R.L.: US20036441193 (2003).
212. Hauser, K.L., Palkowitz, A.D.: US5916916 (1999).
213. Hauser, K.L., Palkowitz, A.D.: US5929090 (1999).
214. Schmidt, J.M., Mercure, J., Lowell, J.L., Kwiatkowski, S., Pupek, K., Zhu, S., Whelan, J., Lazarowych, N.: US20036599921 (2003).
215. Cameron, K.O., Chesworth, R., DaSilva-Jardine, P.A., Day, R.F., Lefker, B.A., Zawistoski, M.P.: US20036608203 (2003).
216. Bhagwat, S.S., Gayo-Fung, L.M., Stein, B.M., Chao, Q., Gangloff, A.R., McKie, J.A., Rice, K.D.: US20036593322 (2003).
217. Kaltenbach, R.F., Robinson, S.P., Trainor, G.L.: US20056927224 (2005).
218. Willson, T.M.: US5681835 (1997).
219. Cooperwood, J.S.: US200511073087 (2005).
220. Mewshaw, R.E., Cohn, E.M.: US200611591039 (2006).
221. Malamas, M.S., Gunawan, I., Harris, H.A., Keith, J.C., Albert, L.M.: US200511093792 (2005).
222. Malamas, M.S., McDevitt R.E., Gunawan, I., Manas, E.S., Collini, M.D., Harris, H.A., Keith, J.C., Albert, L.M., Lyttle, C.R.: US200210309699 (2002).
223. Malamas, M.S., McDevitt, R.E., Gunawan, I., Manas, E.S., Collini, M.D., Harris, H.A., Keith, J.C., Albert, L.M., Lyttle, C.R.: US200611636947 (2006).
224. Jain, N.F., Mecielag, M.J., Murray, W.V., Ng, R.A., Sui, Z.: US200711624808 (2007).
225. Caggiano, T.J., Brazzale, A.A.: US200511124808 (2005).
226. Mewshaw, R.E., Yang, C.: US200410835228 (2004).
227. Bechle, B.M., Chang, G.C., Didiuk, M., Finneman, J.I., Garigipati, R.S., Kelley, R.M., Perry, D.A.: US200310615282 (2003).
228. MacLean, D.B., Thompson, D.D.: US200511071955 (2005).
229. Hermsmeyer, R.K.: US200310690169 (2003).
230. Mewshaw, R.E., Edsall, R.J.: US200611591042 (2006).
231. DiNinno, F.P., Hammond, M.L.: US200310385808 (2003).
232. Mewshaw, R.E., Bowen, S.M., Manas, E.S.: US200711765548 (2007).
233. Sabatucci, J.P., Ye, F., Mahaney, P.E.: US200511305739 (2005).
234. Hoekstra, W.J., Miller, A.B., Zuercher, W.J., Patel, H.S.: US200510598246 (2005).
235. Ruggeri, R.B.: US200410807838 (2004).
236. Miller, C.P., Collini, M.D., Kaufman, D.H., Morris, R.L., Singhaus, R.R., Ullrich, J.W., Harris, H.A., Keith, J.C., Albert, L.M., Unwalla, R.J.: US200410828970 (2004).
237. Mewshaw, R.E., Edsall, R.J., Yang, C., Harris, H.A., Keith, J.C., Albert, L.M.: US200210316640 (2002).
238. Katzenellenbogen, J.A., Katzenellenbogen, B.S., Compton, D.R.: US200611459917 (2006).
239. Tannen RL, Weiner MG, Xie D, Barnhart K. Estrogen affects postmenopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 2007; 22(6): 1769-1777.